Nichols buys VITHIT for €75 million in earnings-enhancing soft drinks deal
Nichols is buying VITHIT for €75 million, gaining a profitable functional drinks brand with growth potential in the UK and overseas.
This article covers information on Nichols PLC.
LON:NICLNichols PLC has acquired functional soft drinks brand VITHIT for €75.0 million, equivalent to approximately £64 million, in a deal designed to strengthen its position in the health and wellness drinks market.
The acquisition is substantial, but it is not a speculative punt on an early-stage brand. VITHIT generated revenue of €26.5 million and adjusted operating profit of €4.2 million in 2025, with an adjusted operating margin of 15.8%.
Nichols expects the deal to enhance earnings immediately, before one-off transaction costs, while supporting growth in earnings per share and dividends per share from the 2027 financial year onwards.
Investors can read the original company announcement for the full details.
The VITHIT acquisition at a glance
| Key figure | Detail |
|---|---|
| Cash consideration | €75.0 million, approximately £64 million |
| VITHIT 2025 revenue | €26.5 million |
| Adjusted operating profit | €4.2 million |
| Adjusted operating margin | 15.8% |
| Adjusted profit before tax | €4.1 million |
| Net assets | €7.7 million |
| Expected annual synergies | More than €1 million |
| One-off transaction costs | Approximately £2.5 million |
| Funding | Nichols' existing cash |
The price is being paid on a debt-free, cash-free basis. That means the agreed valuation assumes VITHIT is acquired without financial debt or surplus cash affecting the headline consideration.
Based on the disclosed 2025 figures, Nichols is paying approximately 2.8 times VITHIT's revenue and 17.9 times adjusted operating profit before synergies. These are simple headline calculations rather than company-provided valuation multiples.
The valuation is not obviously cheap, so successful delivery of the growth and efficiency plans will matter.
What Nichols is buying
Founded in Dublin in 2001, VITHIT sells low-calorie, low-sugar drinks fortified with vitamins and other functional ingredients. Its range includes bottled ready-to-drink products, sparkling cans and effervescent products.
The brand says its drinks provide 100% of the recommended daily allowance of eight essential vitamins.
VITHIT has leading positions in the UK and Ireland, plus a presence in 13 other international markets. Its products are sold through grocery, convenience, foodservice and specialist retail channels.
The financial record presented in the announcement is encouraging. Revenue has grown at a compound annual growth rate, or CAGR, of approximately 9.5% over three years, with sales rising by more than 90% since 2021.
Just as importantly, that expansion has produced established profitability rather than revenue growth alone. A 15.8% adjusted operating margin gives Nichols a meaningful profit base from which to pursue further expansion.
Why VITHIT fits the Nichols strategy
The deal gives Nichols PLC a stronger position in health and wellness, which the board describes as a significant and growing part of the soft drinks market.
There is also a clear operational fit. Both companies use an asset-light model, meaning they rely less heavily on owning capital-intensive manufacturing assets. This should make VITHIT easier to integrate into Nichols' existing structure than a business with a large factory network.
Nichols has identified several potential growth levers:
- expanding VITHIT's UK distribution through existing customer relationships
- increasing its presence within major retail customers
- investing more heavily in the brand
- improving procurement and operational efficiency
- using Nichols' existing infrastructure
- accelerating international expansion through Nichols' established model
The opportunity is therefore broader than simply adding VITHIT's current profits to the group. Nichols believes it can place the brand in more locations, deepen relationships with existing customers and use its international capabilities to reach new consumers.
This follows the group's previously reported strategic initiatives and 2025 profit growth.
Synergies could improve the economics
Nichols expects annual synergies of more than €1 million. Synergies are the additional savings or benefits created by combining two businesses, such as better purchasing terms or sharing existing infrastructure.
If delivered in full, these benefits would represent a meaningful addition to VITHIT's €4.2 million adjusted operating profit. However, Nichols has not disclosed the timing, implementation costs or detailed composition of the expected synergies.
Investors should therefore avoid treating the full amount as guaranteed or immediate.
The company also expects returns to be comfortably above its cost of capital. That is an important statement because a deal can increase earnings while still destroying value if the buyer pays too much. However, the precise expected return has not been disclosed.
Cash funding limits financial risk, but reduces the cushion
Nichols is funding the entire acquisition from cash already held on its balance sheet. Pro forma for the transaction, meaning after adjusting the accounts as if the deal had already happened, the group says it remained net cash positive at 30 June 2026.
That is a reassuring feature. Nichols is not relying on a large acquisition loan or issuing new shares to fund the purchase.
A new revolving credit facility from NatWest will be put in place after completion for working capital purposes. A revolving credit facility is a flexible borrowing arrangement that can be drawn and repaid as required.
The trade-off is that Nichols is committing approximately £64 million of cash, reducing the financial buffer available for other opportunities or unexpected pressures. Management expects strong cash generation to rebuild reserves over time, but the pace of that recovery has not been disclosed.
What happens to the dividend?
Nichols has reaffirmed its recently improved dividend cover policy of 1.5 times. Dividend cover compares earnings with the dividend payment, giving an indication of how comfortably distributions are supported by profit.
The board remains committed to its existing capital allocation framework and dividend policy. Because the acquisition is expected to enhance earnings, Nichols says it should increase earnings per share and consequently dividends per share from FY27 onwards.
No specific dividend forecast or increase has been disclosed.
The main risks for investors
The most immediate risk is execution. VITHIT has performed well independently, but Nichols must now preserve that momentum while integrating the business and pursuing synergies.
Some members of VITHIT's management team will leave after a transition period, while founder and chairman Gary Lavin stepped down from completion. Nichols will retain the Dublin office and receive support from the remaining management team, although leadership changes can still create disruption.
There is also valuation risk. Paying roughly 17.9 times historic adjusted operating profit places weight on future growth and synergy delivery.
Finally, the earnings-enhancement statement excludes approximately £2.5 million of one-off transaction costs. The required IFRS 3 purchase price allocation has not yet been completed, so the accounting impact of acquired intangible assets and related charges will not be clear until the year-end update.
A strategically logical deal with delivery now in focus
VITHIT gives Nichols a profitable, growing brand in a complementary category, supported by strong positions in the UK and Ireland and a foothold across additional international markets.
The cash-funded structure, continued net cash position and expected earnings enhancement are positives. More than €1 million of annual synergies could further improve returns if management delivers its plan.
The key question is whether Nichols can generate enough additional distribution, international growth and efficiency savings to justify the €75.0 million price. The strategic reasoning is clear, but the next stage is about execution rather than acquisition promises.
Related
Keep reading
Investing
AstraZeneca’s Enhertu delivers Phase III lung cancer PFS win
Enhertu delayed disease progression versus standard care in a Phase III lung cancer trial, supporting its potential move into first-line treatment.
JoshuaAugust 17, 2026
Investing
Optima Health FY26 results: growth beats expectations as PAM integration begins
Optima Health beat adjusted EBITDA expectations in FY26, while the £100 million PAM acquisition reshaped its growth prospects and balance sheet.
JoshuaAugust 17, 2026
Investing
Nostrum Oil & Gas Agrees $304.6 Million Kazakhstan Sale Ahead of Wind-Down
Nostrum plans to sell its Kazakhstan operations, repay secured notes in full and begin an orderly wind-down after completion.
JoshuaAugust 17, 2026
Tagged
Last updated
Category
InvestingLikes
Star Rating
No ratings yet
Comments
No comments yet - start the conversation.